Cognitive Decline and Dementia in the Oldest-Old

Efrat Kravitz, M.Sc.1,2, James Schmeidler, Ph.D.3, and Michal Schnaider Beeri, Ph.D.1,3*

1The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel; 2Parkinson’s Disease and Movement Disorders Clinic, Department of Neurology, Sheba Medical Center, Ramat Gan, Israel; and 3Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

ABSTRACT

The oldest-old are the fastest growing segment of the Western population. Over half of the oldest-old will have dementia, but the etiology is yet unknown. Age is the only risk factor consistently associated with dementia in the oldest-old. Many of the risk and protective factors for dementia in the young elderly, such as ApoE genotype, physical activity, and healthy lifestyle, are not relevant for the oldest-old. Neuropathology is abundant in the oldest-old brains, but specific pathologies of Alzheimer's disease (AD) or vascular dementia are not necessarily correlated with cognition, as in younger persons. It has been suggested that accumulation of both AD-like and vascular pathologies, loss of synaptic proteins, and neuronal loss contribute to the cognitive decline observed in the oldest-old. Several characteristics of the oldest-old may confound the diagnosis of dementia in this age group. A gradual age-related cognitive decline, particularly in executive function and mental speed, is evident even in non-demented oldest-old. Hearing and vision losses, which are also prevalent in the oldest-old and found in some cases to precede/predict cognitive decline, may mechanically interfere in neuropsychological evaluations. Difficulties in carrying out everyday activities, observed in the majority of the oldest-old, may be the result of motor or physical dysfunction and of neurodegenerative processes. The oldest-old appear to be a select population, who escapes major illnesses or delays their onset and duration toward the end of life. Dementia in the oldest-old may be manifested when a substantial amount of pathology is accumulated, or with a

§ Special Issue on Ageing, Guest Editor: Nir Barzilai

Abbreviations: AD, Alzheimer’s disease; ADL, Activities of Daily Living; ApoE, apolipoprotein E; BADL, basic ADL; IADL, instrumental ADL; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; NINCDS, National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease; PET, positron emission tomography; VaD, vascular dementia.

Citation: Kravitz E, Schmeidler J, Schnaider Beeri M. Cognitive Decline and Dementia in the Oldest-Old. RMMJ 2012;3 (4):e0026. doi:10.5041/RMMJ.10092

Copyright: © 2012 Kravitz E, et al. This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conflict of interest: No potential conflict of interest relevant to this article was reported.

* To whom correspondence should be addressed. E-mail: Michal.beeri@mssm.edu
composition of a variety of pathologies. Investigating the clinical and pathological features of dementia in the oldest-old is of great importance in order to develop therapeutic strategies and to provide the most elderly of our population with good quality of life.

KEY WORDS: Dementia, epidemiology, neurobiology, oldest-old, risk factors

INTRODUCTION
As life expectancy is steadily increasing,1 the Western population is aging. With the decline in fertility, the extreme elderly are the fastest growing segment of the population. In the US alone, the proportion of those aged ≥85 is expected to increase from less than 2% in 2010, to over 4% in 2050, constituting more than 20% of those aged ≥65.2 Combining the world's more developed regions (Europe, Northern America, Australia/New Zealand, and Japan), by the middle of this century 5.5% of the population will be aged ≥85.3 The fast increase in the proportion of the oldest-old in the population will impose new public health and economic challenges. Within this age group, over half will have dementia,4,5 and the annual incidence rate will double every 5 years.6 Over 10% of the oldest-old will live in skilled-nursing facilities,7 and even more will utilize assisted-living facilities. About 50% of the residents of skilled-nursing facilities in the US are oldest-old.7 Middle-aged individuals will find themselves going from caring for their children to caring for their parents. To date, the current knowledge base of the epidemiology, neuropsychology, and neurobiology of dementia in the oldest-old is inadequate for developing therapeutic strategies. Understanding dementia in extremely old age is therefore crucial for easing the economic and societal burden of caring for our most elderly, which will increase dramatically in the next few decades.

Here we review the neuropsychological and neurobiological characteristics of dementia in very old age, and give special attention to risk and protective factors.

EPIDEMIOLOGY OF DEMENTIA IN THE OLDEST-OLD
Normal aging does not imply unavoidably cognitive decline, and dementia is not an inevitable consequence of old age. According to the DSM-IV, dementia is characterized by the development of multiple cognitive deficits that include memory impairment and at least one of the following cognitive disturbances: aphasia, apraxia, agnosia, or a disturbance in executive functioning; the cognitive deficits must be sufficiently severe to cause impairment in occupational or social functioning and must represent a decline from a previously higher level of functioning.8 Estimates of cognitively intact centenarians are 11%9 to 30%.10–13 Among the oldest-old, estimates of dementia prevalence are about 50%14 to over 60%.15 Nevertheless, the dementia incidence rate is a matter of controversy. Slowing of dementia incidence after age 90 has been found in several studies,15–21 but results from the pioneering “90+ Study,” a study of the neuropsychology and neurobiology of over 1,200 nonagenarians, suggest that the incidence of dementia continues to rise exponentially after the age of 90.22 The all-cause dementia incidence rate was found to increase from 12.7% per year for those aged 90 to 94 years, through 21.2% per year for the group 95 to 99 years old, to 40.7% per year for persons aged 100 years and older, essentially doubling every 5.5 years.22 This increase in incidence rate is comparable with that observed for persons aged 65 to 94 years, which also doubles approximately every 5 years.23 Recent results from the 90+ Study highlights the relevance of the baseline cognitive status of the oldest-old for the observed incidence rate. This study reported that all-cause dementia incidence was highest for participants who, at the beginning of the study, were not demented but had amnestic mild cognitive impairment (MCI) (31.4% per year) and other cognitive impairment (39.9% per year). Participants with normal cognition at the beginning of the study had an incidence of 8.4% per year.24 Differences in evaluation methods and attention to baseline cognitive status may account for some of the differences in results between studies.

The most common subtypes of dementia are Alzheimer’s disease (AD) and vascular dementia (VaD). If incidence rates of AD differ from those of VaD, differences in the composition of the cohort, in terms of dementia subtypes, may account for some differences between studies as well. It is therefore interesting to examine whether the incidence rate of
Cognitive Decline and Dementia in the Oldest-Old

Risk Factors for Dementia in the Oldest-Old

Age
The high rates of incidence and prevalence of dementia in the oldest-old indicate that age is an important risk factor. Although it has been suggested that dementia is an inevitable part of aging,30 dementia could result from the continued accumulation of potentially preventable age-related risk factors,21 eventually surpassing a threshold after which protective mechanisms (such as neuro-immune response) and compensatory facilities (such as reserve capacity) cannot maintain healthy cognition. Since aging is inevitable, managing modifiable risk factors could, at least partially, prevent or delay some of the devastating aspects of extremely old-age dementia.

Estrogen and estrogen therapy
Women’s life expectancy is longer than men’s. Also, sex differences in incidence/prevalence of all-cause dementia, as well as AD and VaD, have been reported in the oldest-old. Results from the 90+ Study suggested higher prevalence (all cases) of all-cause dementia in women than in men,31 although the incidence (“new” cases) rates were similar in both sexes.22 The authors suggested that sex differences in prevalence are due to shorter survival of men after a diagnosis of dementia, as previously reported in younger elderly.32 Examining dementia subtypes, the majority of the reports are in agreement with higher prevalence and incidence rates of AD in extremely old women.19,26,28,33–36 As for VaD, however, higher prevalence and incidence rates in very old men were suggested in some studies,26,27 but not all.25,35,36 One immediate suspect among gender differences is estrogen, the primary female gonadal hormone. Unlike testosterone, the primary male gonadal hormone, which gradually and moderately decreases with male aging,37 estrogen production in women ceases suddenly around the time of menopause.38 Indeed, epidemiological evidence has linked the loss of estrogen with an increased risk for the development of AD, and suggested that estrogen replacement would significantly decrease the incidence of AD (for reviews see39,40). Despite the majority of epidemiological and basic research that suggest...
beneficial actions of estradiol, some clinical trials examining the role of hormone replacement therapy in the development of AD, including the Women’s Health Initiative (WHI), have provided conflicting results.41–43 Finally, it has been suggested that women are at greater risk for dementia and AD simply because they live longer, and thus more likely to develop age-related disorders. A support for this notion came from the Leisure World Cohort Study, which suggested that estrogen therapy is associated with longevity, rather than dementia.44

**Genes**

To date, no clear evidence has shown an association between genetic factors and dementia in the oldest-old. This may seem at odds, since the genetic factors that are most consistently associated with dementia in younger elderly (particularly AD)45 and longevity46 are all related to a specific family of proteins—the lipoproteins. These genetic factors include: 1) the ε4 allele of apolipoprotein E (ApoE) gene that has been independently associated with increased risk of late-onset (age ≥ 65) AD47,48 and reduced chance of becoming a centenarian;49 and the genes for 2) microsomal transfer protein (mediates the rate-limiting step in lipoprotein synthesis); and 3) cholesteryl ester transfer protein (affects HDL and LDL particle size), which have been associated with longevity.50,51 None of these genes were associated with dementia in the oldest-old. In fact, the presence of the ApoE ε4 allele seems to lose its significance in predicting AD as age progresses.52 The lack of associations between dementia and lipoproteins in very old age add further evidence to the hypothesis that the oldest-old are likely to be biologically different from the younger-old.

**Physical activity**

In studies of younger elderly, physical activity has consistently been associated with decreased risk of dementia.53–56 A possible explanation is that physically active individuals are more resistant to adverse risk factor changes, which modulate the risk of dementia, such as diabetes or diabetes-like metabolic disorders (reviewed in57,58) and cardiovascular diseases (reviewed in 59,60). Other mechanisms may involve direct influences of physical activity on brain plasticity61 and structural and functional brain reserves.62 In addition, experimental studies have shown that exercise resulted in a decrease in Aβ plaques in the cerebral cortex and hippocampus in a mouse model for AD,63 and promoted hippocampal neurogenesis in a mouse model for amyotrophic lateral sclerosis.64 Although similar associations between physical activity and dementia may be expected in the oldest-old, such evidence is extremely scarce. Preliminary analyses of the 90+ Study showed that impairment in measures of physical performance (such as timed walking, balance, and hand grip) were associated with increased risk of dementia.6 Nevertheless, data of the 90+ Study from the 1980s associated late-life exercise with longevity, but not dementia.65 In order to assess fully the contribution of physical activity to risk of dementia in the oldest-old, exercise and activeness should be objectively evaluated in real time, years before the onset of dementia. This requires long prospective studies, which are currently unavailable.

**Lifestyle**

Similar to physical activity, other lifestyle-related factors have been associated with longevity. Those factors include eating habits reflected in body mass index (both being underweight and being obese increased the risk of mortality),66 alcohol consumption (more than 2 drinks per day reduced the risk of death by 15%),67 and caffeine intake (with a U-shaped mortality curve).68 None of these factors, however, were associated with prevalent dementia in the oldest-old.6

In summary, many of the risk and protective factors for dementia in the young elderly are not relevant for the oldest-old. Out of the reviewed factors, only age was consistently associated with dementia in the oldest-old. Estrogen showed some association with dementia in the oldest, but this association was not consistent through all studies and dementia subtypes. The other factors—the ε4 allele of the ApoE gene, physical activity, and healthy lifestyle—which were all associated with dementia in younger elderly, were not associated with dementia in the oldest-old. This difference supports the potential for differential neurobiology of AD and dementia in the oldest-old.

**Neurobiological Changes in Dementia of the Oldest-Old**

“Dementia” is a general term for a group of disorders, and the distinction between dementia subtypes is largely dependent on their underlying neuropathology. Hence, for the most part, the following discussion describes the associations...
between pathologies of specific dementia subtypes and the clinical manifestation of general dementia symptoms. The major pathological hallmarks of AD, extracellular deposits of amyloid protein which form neuritic plaques and intraneuronal neurofibrillary tangles, are found with increasing frequency in advancing age. The age-related increases in AD pathologies, together with the increased incidence rates of dementia with age, suggest that the two are related. Recent studies, however, have shown that the association between the pathological features of AD and dementia is stronger in younger persons than in the oldest-old. This lack of association was found to be due to both high prevalence of cerebral pathologies in some non-demented oldest-old and low prevalence of these pathologies in many demented oldest-old. Moreover, in the oldest-old, an ApoE ε2 allele—which is considered protective against AD—was associated with a somewhat reduced risk of dementia, despite its association with increased AD neuropathology. Some of the above-mentioned studies (e.g.,) found these weaker relationships in the oldest-old not only for AD pathology, but also for other types of neuropathologies (hippocampal sclerosis, atrophy, vascular dementia, and diffuse Lewy body disease). Consistent with that, cerebrovascular pathologies, such as small-vessel disease and/or infarcts, were strongly associated with dementia in younger elderly but not in the oldest-old.

Contrary to these findings, a recent study from the Baltimore Longitudinal Study of Aging found that plaques and tangles were significant predictors of dementia independent of age. This study also found that in participants older than 90 years of age, intracranial atherosclerosis predicted dementia in subjects with low Alzheimer’s pathology scores. A study of a relatively large number of autopsies found that mixed AD pathology and vascular pathology accounted for most dementia cases in very old persons. The cumulative effects of AD-type pathologies and vascular pathologies on cognition have been demonstrated in several studies.

Another feature of aging and dementia is synaptic protein loss, which may dissociate oldest-old individuals with and without dementia. Head and colleagues studied several synaptic proteins in the frontal cortex of aged individuals (92–105 years) with a range of cognitive function. Synaptophysin protein levels were lower in individuals with dementia and correlated with cognitive function scores. The investigators concluded that these protein levels may protect neuronal function in oldest-old individuals and reflect compensatory responses that may be involved with maintaining cognition. Similarly to these findings, we have also found that gene and protein expression levels of synaptic markers decrease in persons with dementia, regardless of age.

This considerable discrepancy between pathology and dementia in the oldest-old has focused attention on the importance of neuronal loss, rather than the accumulation of abnormal protein deposits, in causing cognitive impairment. Contrary to the traditional view, it now appears that neuron loss is restricted in normal brain aging and unlikely to account for age-related impairment of neocortical and hippocampal functions. Consistent with this idea, Savva et al. found that neocortical cerebral atrophy maintained a relationship with dementia across all age groups. The value of cerebral atrophy in predicting dementia was supported by in vivo and postmortem magnetic resonance imaging (MRI) studies. Specifically, a study from our group showed reduced functional MRI (fMRI) activation in highly functioning nonagenarians during a recognition memory task, as compared to younger subjects, suggesting effective usage of cognitive reserve. The association between neuronal loss and cognitive impairment, and the lack of association between AD/vascular pathologies and cognitive impairment, has led to the construct of “cognitive reserve,” the hypothesized capacity of the mature adult brain to resist the effects of disease or injury that would otherwise cause dementia. According to this hypothesis, elderly individuals with a high level of cognitive reserve may remain dementia-free in spite of the neuropathological changes. Several factors that predict lower risk of dementia, including high-quality education, occupational complexity, and balanced diet, were also associated with the biological advantage of cognitive ability, i.e. cognitive reserve (reviewed in). A recent study by Murray et al. demonstrates that the magnitude of the contribution of education to cognitive function is greater than the negative impact of either of the two neuropathological burdens alone, emphasizing the role of both neuronal loss and neuronal reserve in the dementing processes of the oldest-old.
Cognitive Decline and Dementia in the Oldest-Old

Symptomatology of Dementia in the Oldest-Old

Cognitive Decline

Even without a “proper” dementia diagnosis, it is generally accepted that—on average—a gradual age-related cognitive decline occurs in humans, as well as non-human primates. Cognitive performance is a term that describes the composite outcome of multiple cognitive domains and the interactions between them. Therefore, “cognitive decline” may be the result of impairment in an individual domain or impairment in multiple domains, possibly to different extents. Studies have described age-related declines in many of the cognitive domains, including divided attention, verbal memory, working memory, and learning. Nevertheless, it appears that during normal aging, some domains are more susceptible to impairment than others. In particular, executive function and mental speed have been suggested as such vulnerable domains.

This poses a new challenge on determining diagnosis of AD and other forms of dementia in the oldest-old. In spite of the great development in neuroimaging techniques such as MRI and positron emission tomography (PET), neuropsychological assessment remains the key instrument in diagnosing dementia and monitoring cognitive decline.

Several valid and reliable neuropsychological dementia screening instruments have been developed to address the issue of clinical dementia diagnosis in elderly in whom cognitive decline is expected. Those instruments include the Blessed Dementia Scale, Dementia Rating Scale, Mini-Mental State Examination (MMSE), and Modified Mini-Mental State Examination (3MS)—an expanded version of the MMSE. The MMSE is probably the most widely used, easy to administrate, cognitively comprehensive, and validated instrument for detecting dementia. It has also been validated in the oldest-old, as it was found to have good sensitivity and specificity across all age and educational groups.

According to the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA), in order to fulfill research criteria for probable AD, a patient must 1) meet the core clinical criterion A—significant episodic memory impairment; 2) meet at least one of the supportive biomarker criteria—medial temporal lobe atrophy (criterion B), abnormal cerebrospinal fluid biomarker (criterion C), specific pattern on functional neuroimaging with PET (criterion D), or proven AD autosomal dominant mutation within the immediate family (criterion E); and 3) all other possible medical, psychiatric, and neurological explanations for the symptoms have been ruled out. Strikingly, these criteria are pertinent only to individuals below the age of 90.

Given the age-related cognitive decline described above, it is essential to set norms suitable for the oldest-old in order to make a reliable diagnosis. Using the 90+ study, Whittle et al. compiled a relatively brief test battery for multiple cognitive domains, with an average time to complete of one hour. This study found that in non-demented oldest-old, cognitive performance declined with age for two-thirds of the tests, and a high prevalence (34%) of cognitive impairment was observed in a sample of non-demented oldest-old in another study from the same group. Studies from our group demonstrated that declines in cognitive performance are found even when comparing individuals aged 85–89 to those aged 90+ years, and that the rate of cognitive decline is faster in questionably demented nonagenarians compared to younger groups.

Similarly, cross-sectional studies have compared cognitive abilities of disease-free 100-year-olds to those of younger age groups. For instance, Poon et al. found that centenarians performed significantly lower on verbal and performance measures than 60- to 80-year-olds but did not differ in their ability to solve practical problems. Similar findings were reported with Swedish centenarians on new learning and working memory tests compared with 16- to 57-year-olds.

In conclusion, the oldest-old have lower cognitive functioning and faster cognitive decline than younger elderly, and this decline affects cognition globally.

Sensory and Motor Disability

It seems to be commonly understood that very old people suffer from sensory losses and reduced physical and motor abilities. Extremely old individuals are typically portrayed in movies as having hunched walk, thick glasses, and loud speech, and replying with “What?!?” shouts to every question. This stereotypical presentation of old age...
sensory loss, especially vision impairment, is truly biologically associated with cognitive decline. It has been shown that poor vision precedes dementia, especially vision impairment, is truly biologically associated with cognitive decline. It has been shown that poor vision precedes dementia,121 even when evaluated using the blind version of MMSE.123 An underlying biological mechanism for this association is suggested by several lines of evidence: AD patients often have retinal nerve degenerative changes,124 caused by reduced numbers of ganglion cells and axons125,126 and retinal amyloid plaques accumulation.127 In addition, diabetic retinopathy has been associated with cognitive decline.128 Several studies further suggested that treatment of specific visual disorders could alleviate cognitive decline,121,129,130 although caution must be applied when interpreting the treatment effect as “causative.” Nevertheless, postoperative increase in visual cortex grey matter volume was observed after cataract surgery,131 and disrupting retinoid signaling pathway in rats resulted in loss of choline acetyl transferase expression and amyloid β deposition in cerebral blood vessels,132 suggesting that the relationship between visual impairment and cognitive decline is not merely a mechanical artifact.

As cognitive decline and dementia are very common in the oldest-old (as described above), it has been suggested that sensory disabilities play a role in cognitive functions of the very old. For instance, greater hearing loss was associated with the severity of cognitive dysfunction in a dose-response manner, in both demented patients and normal controls.129 However, hearing and vision losses may “mechanically” interfere in cognitive performances during neuropsychological evaluations, and result in false-positive classification of impaired performances as dementia. Gussekloo et al. reported that although both hearing impairment (prevalence 85%) and visual impairment (prevalence 59%) were associated with global cognitive impairment, only visual impairments were also associated with poorer scores on memory and cognitive speed, as measured with visually presented cognitive tests.116 This suggests practical disadvantage of sensory impairment during cognitive assessments. In order to compensate for vision and hearing loss when assessing the oldest-old, using their experience in the 90+ Study, Brumback-Peltz et al. suggested some standardized changes in administration methods.29 These changes include providing amplified auditory and visual stimuli, and modifying common neuropsychological tests to include large type-face cards that are presented simultaneously with auditory tasks, spoken in a loud, clear voice.29

On the other hand, some studies suggest that sensory loss, especially vision impairment, is truly biologically associated with cognitive decline. It has been shown that poor vision precedes dementia,121 and vision impairment predicts cognitive decline,122 even when evaluated using the blind version of MMSE.123 An underlying biological mechanism for this association is suggested by several lines of evidence: AD patients often have retinal nerve degenerative changes,124 caused by reduced numbers of ganglion cells and axons125,126 and retinal amyloid plaques accumulation.127 In addition, diabetic retinopathy has been associated with cognitive decline.128 Several studies further suggested that treatment of specific visual disorders could alleviate cognitive decline,121,129,130 although caution must be applied when interpreting the treatment effect as “causative.” Nevertheless, postoperative increase in visual cortex grey matter volume was observed after cataract surgery,131 and disrupting retinoid signaling pathway in rats resulted in loss of choline acetyl transferase expression and amyloid β deposition in cerebral blood vessels,132 suggesting that the relationship between visual impairment and cognitive decline is not merely a mechanical artifact.

Similarly to cognition and sensory abilities, motor abilities (as speed and power) and physical performance also decline with age. Moreover, it appears that these motor and physical declines may be associated with declines in cognition133 and an increased risk of dementia, disability, and death. Earlier we have reviewed studies that suggest physical activity may be protective against dementia and cognitive decline. However, the physical and motor disabilities that are common in the oldest-old population are likely to prevent them from performing physical activity. These disabilities may well precede cognitive decline, and therefore may reflect common pathways in age-associated mechanisms of physical and cognitive decline.

Disability and Activities of Daily Living
Comorbidity is very common among the oldest-old. Suffering from neurodegenerative disorder or related medical illness may result in difficulties in carrying out every-day activities. The 90+ Study found that almost all participants had at least one major medical illness or cardiovascular risk factor, and 62% had two or more.134 In centenarians it was found that, on average, they had more than four chronic conditions or diseases.135

Physical disability, medical illness, and cognitive impairment can all contribute to functional disability, presented as functional losses in activities such as driving and managing financial matters. Therefore, functional disability is expected to be very prevalent in the oldest-old. A study of people aged 84–90 found a minority (23%) of high-functioning subjects with no or only mild disability.136 In addition, the 90+ Study found that, overall, 16.4% became disabled each year, and that the disability incidence increased with age from...
8.3% in the 90–94 age group to 25.7% in the 95 years and older age group.\textsuperscript{134}

A widely accepted measure of disability is the index of Activities of Daily Living (ADL), including basic ADLs (BADLs)\textsuperscript{137} and instrumental ADLs (IADLs).\textsuperscript{138} Grades of the BADLs summarize overall performance in self-care tasks, such as bathing, dressing, using the toilet, transferring, continence, and feeding. IADLs include tasks such as housework, taking medication as prescribed, managing money, shopping for groceries, and using technology. IADLs consist of tasks which are not necessary for fundamental functioning, but they let an individual live independently in a community.\textsuperscript{139} IADL independence is one of the defining features that distinguishes normal aging from mild cognitive impairment (MCI) and dementia,\textsuperscript{140} whereas losses in the ability to perform BADL are characteristics of moderate to severe dementia.\textsuperscript{141} For instance, a positive relationship has been observed between the level of cognitive impairment and the decline in IADLs such as managing money, telephone use, preparing meals, and medications.\textsuperscript{142} A recent study found that lower Dementia Rating Scale scores were associated with greater reported difficulties and impairments in ADLs, as follows: 1) participants in the “mild” range of cognitive impairment were most likely to have difficulties with IADLs such as household upkeep, managing finances, and functioning outside a familiar environment; 2) a large proportion of individuals with “moderate” cognitive impairment reported difficulty with washing/grooming and dressing (BADLs), and additionally reported difficulty to some degree in all of the IADLs; 3) individuals in the “severe” cognitive impairment range were likely to have difficulties with all BADLs, and over 85% of the severe group reported difficulty in all IADLs.\textsuperscript{143}

Losses in the ability to perform ADLs are very common in the oldest-old. Difficulty in one or more BADLs was present in 71% of 90–94-year-olds, 89% of 95–99-year-olds, and 97% of centenarians, with walking as the BADL most commonly causing difficulty (76%), and bathing as the BADL most commonly causing dependency (51%). Bathing is described as a “sentinel event in the disabling process,”\textsuperscript{145} and those unable to bathe themselves without help are more likely to need long-term care.\textsuperscript{146} In what seems to be a conflicting result, a recent publication of the Newcastle 85+ study reported that, of the different ADLs, “cutting toenails” was the first item with which participants had difficulty and “feeding” the last.\textsuperscript{147} In this study, however, the results rely on self-reports, indicating that the study population consisted of higher-performing individuals. There is scarce information on the extent of the contribution of ADL and IADL to oldest-old dementia.

Functional disabilities which extend beyond the specified ADLs have also been associated with aging and dementia. Fine hand motor function (e.g. precision pinch) and gross hand motor function (e.g. pinch and grip force) decline with age\textsuperscript{148} and are associated with MCI and, to a larger extent, with AD (reviewed in\textsuperscript{149}). Impairment in hand-motor activity is likely to contribute to the high prevalence of difficulties in performing IADLs observed in the oldest-old.

DISCUSSION

The increase in the proportion of the oldest-old in the Western population and the increased prevalence of dementia in this age group emphasize the importance of giving extra attention to investigating its specific characteristics. This is not an easy task, since the majority of the oldest-old suffer from many medical conditions, age-related cognitive decline, sensory and motor disabilities, and disabilities in performing everyday activities. This group also presents neurobiological features which differ from younger elderly, including great variability, making interpretation of their contribution to dementia more complex. To complicate characterization further, risk factors for dementia in the oldest-old do not seem to comply with those in young elderly, with age being the only significant risk factor.

These differences raise the question whether the oldest-old are a select population, predisposed to longevity by a veiled biological mechanism, and promoted by modern healthcare. If so, normal aging processes cannot be inferred by investigating the oldest-old, and dementing processes in the oldest-old cannot be inferred from those in young elderly. Consistent with the notion of selected population, the “compression of morbidity” hypothesis proposes that individuals who reach the limits of the human life-span compress the onset and duration of illnesses toward the end of life.\textsuperscript{150} It has been shown that over 83% of centenarians delayed (to their ninth decade or later) or escaped the most lethal diseases of the elderly population, i.e. heart disease, non-skin cancer, and stroke.\textsuperscript{151} Moreover, “delayers” and “escapers” may be two distinct populations.
Escaping lethal diseases by the age of 100 suggests an innate advantage, a “fountain of youth” sort of mechanism, which acts throughout life from early development. Richard Cutler, in his classic paper in gerontology, proposed that persons who achieve extreme old age have genetic variations that affect the basic mechanisms of aging and promote a decreased susceptibility to age-associated diseases.\textsuperscript{152} The decreased susceptibility may be due to the absence of “disease genes,”\textsuperscript{153} or due to the presence of “longevity-enabling genes” that confer protection against the basic mechanisms of aging or age-related illnesses.\textsuperscript{49} In support of this notion, evidence from studies of centenarian pedigrees showed that their family members are more likely to have such combinations of factors in common than the general population, as they had much lower death rates than those of the general population (reviewed in\textsuperscript{154}). The genetic and neurobiological composition of the “escapers” is therefore unique and may present a basis for investigations of protective factors for healthy aging and cognition. Since, overall, the data on the oldest old, and particularly on dementia, are scarce, interpretations must be made with caution.

Achieving exceptional longevity by delaying age-related diseases, however, offers a much less dramatic approach. In this approach, different levels of risk factors, some of them potentially modifiable, will determine the individual’s probability of remaining in good health when others of this age group succumb to illness.

By itself, the notion of delaying or escaping diseases until exceptional old age cannot explain the difficulty in characterizing the etiology of dementia in the oldest-old. The principle of demographic selection dictates that the oldest-old are more similar to one another, genetically and environmentally, than younger elderly individuals, where, theoretically, more heterogeneity is evident. This appears to contradict the great variability in neurobiological features observed in this age group. However, in the oldest-old, the biological phenotypes are only weakly associated with cognition,\textsuperscript{4} possibly reflecting age-related accumulation of varied biological features. As the oldest-old group is probably composed of individuals who are genetically resilient (“escapers”) or with low levels of risk factors (“delayers”) for developing disease, it is with reason that dementing processes will be manifested at levels of pathologies which are different than those of younger elderly. In delayers, low levels of risk factors will result in a low rate of accumulation of pathologies, eventually surpassing the threshold for cognitive decline. In these individuals, the association between cognitive decline and neuropathological features is expected to resemble the association in younger elderly. In escapers on the other hand, the composition, rather than amount, of the accumulated pathologies is likely to play a bigger role in cognition—a large variety of minimal pathologies (each one by itself is not sufficient for causing dementia) will trigger the dementing processes. The greater proportion of resilient individuals in the oldest-old, compared to younger population, may account for the diminished association between pathology and cognition. The fact that not all oldest-old are necessarily resilient, may explain the discrepancies in findings in different studies.

To date, research of the oldest-old is limited not only by the medical and physical features of extreme age, but also by administrative considerations. The NINCDS gold standard for AD clinical diagnostic criteria are limited to age 90,\textsuperscript{155} leading to exclusion of those at highest risk from major international studies. Thus, raising the awareness of the clinical and pathological meaning of dementia in the oldest-old is of enormous urgency. Only extensive research will enable us to provide this rapidly growing population with good quality of life and graceful aging.

REFERENCES

1. World Health Organization. World Health Statistics Report [database on the Internet]. 2011. Available at: http://tinyurl.com/cjxoeqa. Accessed April 8, 2012.

2. United States Census Bureau. Projections of the Population by Selected Age Groups and Sex for the United States: 2010 to 2050 [database on the Internet]. 2008. Available at: http://tinyurl.com/4sv5j2. Accessed April 08, 2012.

3. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects, The 2010 Revision [database on the Internet]. 2011. Available at: http://tinyurl.com/bngtvqz. Accessed April 8, 2012.

4. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009;360:2302–9. Full Text

5. Poon LW, Woodard JL, Stephen Miller L, et al. Understanding dementia prevalence among centenarians. J Gerontol A BiolSci Med Sci 2012;67:358–65. Full Text
6. Kawas CH. The oldest old and the 90+ Study. Alzheimer’s Dement 2008;4(1 Suppl 1):S56–9. Full Text
7. Werner CA. The Older Population: 2010 Census Briefs. United States Census Bureau; 2011. Available at: http://2010.census.gov/2010census/. Accessed April 8, 2012.
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press; 2000.
9. Thomassen R, van Schaick HW, Blansjaar BA. Prevalence of dementia over age 100. Neurology 1998;50:283–6. Full Text
10. Andersen-Ranberg K, Vasgaard L, Jeune B. Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 2001;56:152–9. Full Text
11. Silver MH, Jilinskaia E, Perls TT. Cognitive functional status of age-confirmed centenarians in a population-based study. J Gerontol B Psychol Sci Soc Sci 2001;56:134–40. Full Text
12. Hagberg B, Bauer Alfredson B, Poon LW, Homma A. Cognitive functioning in centenarians: a coordinated analysis of results from three countries. J Gerontol B Psychol Sci Soc Sci 2001;56:141–51. Full Text
13. Silver M, Newell K, Hyman B, Growdon J, Hedley-Whyte ET, Perls T. Unraveling the mystery of cognitive changes in old age: correlation of neuropsychological evaluation with neuropathological findings in the extreme old. Int Psychogeriatr 1998;10:25–41. Full Text
14. Green MS, Kaye JA, Ball MJ. The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old. Neurology 2000;54:105–13. Full Text
15. Hagnell O, Ojesjo L, Rorsman B. Incidence of dementia in the Lundby Study. Neuroepidemiology 1992;11(Suppl):61–6. Full Text
16. Fichter MM, Schroppel H, Meller I. Incidence of dementia in a Munich community sample of the oldest old. Eur Arch Psychiatry Clin Neurosci 1996;246:320–8. Full Text
17. The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology 2000;55:66–73. Full Text
18. Ruitenber GA, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22:575–80. Full Text
19. Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol 2002;59:1589–93. Full Text
20. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002;58:209–18. Full Text
21. Hall CB, Verghese J, Sliwinski M, et al. Dementia incidence may increase more slowly after age 90: results from the Bronx Aging Study. Neurology 2005;65:882–6. Full Text
22. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ Study. Ann Neurol 2010;67:114–21. Full Text
23. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998;51:728–33. Full Text
24. Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments. Neurology 2011;77:1906–12. Full Text
25. Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E. Incidence of vascular dementia in Rochester, Minn, 1985–1989. Arch Neurol 2002;59:1605–10. Full Text
26. Lopez-Pousa S, Vilalta-Frankh J, Llinas-Regla J, Garre-Olmo J, Roman GC. Incidence of dementia in a rural community in Spain: the Girona cohort study. Neuroepidemiology 2004;23:170–7. Full Text
27. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737–46. Full Text
28. Fratiglioni L, Viitanen M, von Strauss E, Tomotdonavi V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997;48:132–8. Full Text
29. Brumback-Peltz C, Balasubramanian AB, Corrada MM, Kawas CH. Diagnosing dementia in the oldest-old. Maturitas 2011;70:164–8. Full Text
30. Drachman DA. If we live long enough, will we all be demented? Neurology 1994;44:1563–5. Full Text
31. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ Study. Neurology 2008;71:337–43. Full Text
32. Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a
33. Letenneur L, Gillieron V, Commenges D, Helmer C, Orgogozo JM, Dartigues JF. Are sex and educational level independent predictors of dementia and Alzheimer’s disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry 1999;66:177–83. Full Text

34. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999;53:1992–7. Full Text

35. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(Suppl 5):S10–15.

36. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(Suppl 5):S4–9.

37. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724–31. Full Text

38. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257–75. Full Text

39. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer’s disease: the story so far. Drugs Aging 2002;19:405–27. Full Text

40. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 1997;48(Suppl 7):S27–35. Full Text

41. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study. Am J Epidemiol 1994;140:262–7.

42. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2947–58. Full Text

43. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–62. Full Text

44. Paganini-Hill A, Corrada MM, Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause 2006;13:12–18. Full Text

45. Cacabelos R, Martinez-Bouza R. Genomics and pharmacogenomics of dementia. CNS Neurosci Ther 2011;17:566–76. Full Text

46. Perls T, Kunkel LM, Puca AA. The genetics of exceptional human longevity. J Am Geriatr Soc 2002;50:359–68. Full Text

47. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–3. Full Text

48. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997;277:822–4. Full Text

49. Schacter F, Faure-Delanef L, Guenot F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29–32. Full Text

50. Geesaman BJ, Benson E, Brewster SJ, et al. Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan. Proc Natl Acad Sci U S A 2003;100:14115–20. Full Text

51. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030–40. Full Text

52. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999;53:321–31. Full Text

53. Wang L, Larson EB, Bowen JD, van Belle G. Performance-based physical function and future dementia in older people. Arch Intern Med 2006;166:1115–20. Full Text

54. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;58:498–504. Full Text

55. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012;78:1323–9. Full Text

56. Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. JAMA 2004;292:1447–53. Full Text
57. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 2012;9:35–66. Full Text
58. Ravona-Springer R, Schnaider-Beeri M. The association of diabetes and dementia and possible implications for nondiabetic populations. Expert Rev Neurother 2011;11:1609–17. Full Text
59. Kovacic JC, Castellano JM, Fuster V. The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Ann N Y Acad Sci 2012;1254:99–105. Full Text
60. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–713. Full Text
61. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002;25:295–301. Full Text
62. Scarmeas N, Zarahn E, Anderson KE, et al. Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol 2003;60:359–65. Full Text
63. Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J Neurosci 2005;25:4217–21. Full Text
64. Ma X, Hamadeh MJ, Christie BR, Foster JA, Tarnopolsky MA. Impact of treadmill running and sex on hippocampal neurogenesis in the mouse model of amyotrophic lateral sclerosis. PLoS One 2012;7:e96048. Full Text
65. Kawas C, Corrada M, Paganini-Hill A, et al. Low weight in early adulthood and later life exercise increase chances of surviving to age 90. Neurology 2003;60(Suppl 2):S58.002.
66. Corrada MM, Kawas CH, Mozaffar F, Paganini-Hill A. Association of body mass index and weight change with all-cause mortality in the elderly. Am J Epidemiol 2006;163:938–49. Full Text
67. Paganini-Hill A, Kawas CH, Corrada MM. Type of alcohol consumed, changes in intake over time and mortality: the Leisure World Cohort Study. Age Ageing 2007;36:203–9. Full Text
68. Paganini-Hill A, Kawas CH, Corrada MM. Non-alcoholic beverage and caffeine consumption and mortality: the Leisure World Cohort Study. Prev Med 2007;44:305–10. Full Text
69. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–7. Full Text
70. Imho A, Kovari E, von Gunten A, et al. Morphological substrates of cognitive decline in nonagarians and centenarians: a new paradigm? J Neurol Sci 2007;257:72–9. Full Text
71. Crystal H, Dickson D, Fulp P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology 1988;38:1682–7. Full Text
72. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138–44. Full Text
73. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026–36. Full Text
74. Silve MH, Newell K, Brady C, Hedley-White ET, Perls TT. Distinguishing between neurodegenerative disease and disease-free aging: correlating neuropsychological evaluations and neuropathological studies in centenarians. Psychosom Med 2002;64:493–501.
75. Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB. The relative frequency of “dementia of unknown etiology” increases with age and is nearly 50% in nonagarians. Arch Neurol 2000;57:713–9. Full Text
76. Polvikoski T, Sulkava R, Myllykangas L, et al. Prevalence of Alzheimer’s disease in very elderly people: a prospective neuropathological study. Neurology 2001;56:1690–6. Full Text
77. Corrada M, Head E, Kim R, Kawas C. Braak and Braak staging and dementia in the oldest-old: Preliminary results from the 90+ Study. Neurology 2005;64(Suppl 1):A276.
78. Haroutunian V, Schnaider-Beeri M, Schmeidler J, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 2008;65:1211–7. Full Text
79. Berlau DJ, Corrada MM, Head E, Kawas C. APOE epsilon4 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 2009;72:829–34. Full Text
80. Dolan D, Troncoso J, Resnick SM, Crain BJ, Zonderman AB, O’Brien RJ. Age, Alzheimer’s disease and dementia in the Baltimore Longitudinal Study of Ageing. Brain 2010;133(Pt 8):2225–31. Full Text
81. Jellinger KA, Attens J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 2010;119:421–33. Full Text
Cognitive Decline and Dementia in the Oldest-Old

82. Nagy Z, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56:165–70. Full Text
83. Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813–7. Full Text
84. Head E, Corrada MM, Kahle-Wrobleski K, et al. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging 2009;30: 1125–34. Full Text
85. Schnaider Beeri M, Haroutunian V, Schmeidler J, et al. Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiol Aging 2012;33:1125.e1–8.
86. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412–9. Full Text
87. Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009;72:999–1007. Full Text
88. Morra JH, Tu Z, Apostolova LG, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer’s disease, mild cognitive impairment, and elderly controls. Neuroimage 2009;45(1 Suppl):S3–15. Full Text
89. Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007;69: 1521–7. Full Text
90. Beeri MS, Lee H, Cheng H, Wollman D, Silverman JM, Prohovnik I. Memory activation in healthy nonagenarians. Neurobiol Aging 2011;32:515–23. Full Text
91. Whalley LJ, Deary IJ, Appleton CL, Starr JM. Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev 2004;3:369–82. Full Text
92. Murray AD, Staff RT, McNeil CJ, et al. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer’s diseases. Brain 2011;134:3687–96. Full Text
93. Picq JL, Aujard F, Volk A, Dhenain M. Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. Neurobiol Aging 2012;33: 1096–109. Full Text
94. Salhoute SA. The processing-speed theory of adult age differences in cognition. Psychol Rev 1996;103: 403–28. Full Text
95. Salhoute SA, Atkinson TM, Berish DE. Executive functioning as a potential mediator of age-related cognitive decline in normal adults. J Exp Psychol Gen 2003;132:566–94. Full Text
96. Shaw RJ, Craik FI. Age differences in predictions and performance on a cued recall task. Psychol Aging 1989;4:131–5. Full Text
97. Morris RG, Craik FI, Gick ML. Age differences in working memory tasks: the role of secondary memory and the central executive system. Q J Exp Psychol A 1990;42:67–86. Full Text
98. Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG. Memory function in normal aging. Neurology 1992;42:396–401. Full Text
99. Youngjohn JR, Crook TH 3rd. Learning, forgetting, and retrieval of everyday material across the adult life span. J Clin Exp Neuropsychol 1993;15:447–60. Full Text
100. Salthouse TA. The processing-speed theory of adult age differences in cognition. Psychol Rev 1996;103: 403–28. Full Text
101. Salthouse TA, Hoyer PR. Life and death of neurons in the aging brain. Science 1997;278:412–9. Full Text
102. Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009;72:999–1007. Full Text
103. Mattis S. Dementia Rating Scale: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1988.
104. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98. Full Text
105. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314–8.
106. Tombough TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922–35.
107. Malloy PF, Cummings JL, Coffey CE, et al. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 1997;9:189–97.
108. Kahi-Wrobleski K, Corrada MM, Li B, Kawas CH. Sensitivity and specificity of the mini-mental state examination for identifying dementia in the oldest-old: the 90+ Study. J Am Geriatr Soc 2007;55:284–9. Full Text
109. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46. Full Text
110. Whittle C, Corrada MM, Dick M, et al. Neuropsychological data in nondemented oldest old: the 90+ Study. J Clin Exp Neuropsychol 2007;29:290–9. Full Text

111. Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Cognitive impairment in nondemented oldest-old: prevalence and relationship to cardiovascular risk factors. Alzheimers Dement 2012;8:87–94. Full Text

112. Beeri MS, Schmeidler J, Sanoh M, et al. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006;67:1006–10. Full Text

113. Ravona-Springer R, Luo Y, Schmeidler J, et al. The association of age with rate of cognitive decline in elderly individuals residing in supporting care facilities. Alzheimer Dis Assoc Disord 2011;25:312–6. Full Text

114. Poon LW, Martin P, Clayton GM, Messner S, Noble CA, Johnson MA. The influences of cognitive resources on adaptation and old age. Int J Aging Hum Dev 1992;34:31–46. Full Text

115. Samuelsson SM, Alfredson BB, Hagberg B, et al. The Swedish Centenarian Study: a multidisciplinary study of five consecutive cohorts at the age of 100. Int J Aging Hum Dev 1997;45:223–53. Full Text

116. Gussekloo J, de Craen AJ, Oubber C, van Boxtel MP, Westendorp RG. Sensory impairment and cognitive functioning in oldest-old subjects: the Leiden 85+ Study. Am J Geriatr Psychiatry 2005;13:781–6.

117. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–72. Full Text

118. Cruickshanks KJ, Wiley TL, Tweed TS, et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin. The Epidemiology of Hearing Loss Study. Am J Epidemiol 1998;148:879–86. Full Text

119. Kahle-Wrobleski K, Corrada N, Kawas C. Dementia and Cognition in the Oldest-old. In: Miller BL, Boeve BF, eds. The Behavioral Neurology of Dementia. Cambridge UK: Cambridge University Press; 2009: 254–63. Full Text

120. Uhlmann RF, Larson EB, Rees TS, Koepsell TD, Duckert LG. Relationship of hearing impairment to dementia and cognitive dysfunction in older adults. JAMA 1989;261:1916–9. Full Text

121. Rogers MA, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. Am J Epidemiol 2010;171:728–35. Full Text

122. Lin MY, Gutierrez PR, Stone KL, et al. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc 2004;52:1996–2002. Full Text

123. Reyes-Ortiz CA, Kuo YF, DiNuzzo AR, Ray LA, Raji MA, Markides KS. Near vision impairment predicts cognitive decline: data from the Hispanic Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc 2005;53:681–6. Full Text

124. Lu Y, Li Z, Zhang X, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci Lett 2010;480:69–72. Full Text

125. Iser PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 2006;26:18–24. Full Text

126. Kesler A, Vakhapova V, Korczyk AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg 2011;113:523–6. Full Text

127. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011;54(Suppl 1):S204–17. Full Text

128. Ding J, Strachan MW, Reynolds RM, et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010;59:2883–9. Full Text

129. Fagerstrom R. Correlations of memory and learning with vision in aged patients before and after a cataract operation. Psychol Rep 1992;71(3 Pt 1):675–86.

130. Tamura H, Tsukamoto H, Mukai S, et al. Improvement in cognitive impairment after cataract surgery in elderly patients. J Cataract Refract Surg 2004;30:598–602. Full Text

131. Lou AR, Madsen KH, Julian HO, et al. Postoperative increase in grey matter volume in visual cortex after unilateral cataract surgery. Acta Ophthalmol 2011 Nov 22. [Epub ahead of print]. Full Text

132. Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 2004;20:896–902. Full Text

133. Wilson RS, Bienias JL, Evans DA, Bennett DA. The Religious Orders Study: overview and relation between change in cognitive and motor speed. Aging Neuropsychol Cogn 2004;11(2/3):280–303. Full Text

134. Berlau DJ, Corrada MM, Peltz CB, Kawas CH. Disability in the oldest-old: incidence and risk factors
135. Andersen-Ranberg K, Schroll M, Jeune B. Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians. J Am Geriatr Soc 2001;49:900–8. Full Text

136. Zarit SH, Johansson B, Berg S. Functional impairment and co-disability in the oldest old. J Aging Health 1993;5:291–305. Full Text

137. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–9. Full Text

138. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–86. Full Text

139. Bookman A, Harrington M, Pass L, Reisner E. Family Caregiver Handbook. Cambridge, MA: Massachusetts Institute of Technology; 2007.

140. Gold DA. An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment. J Clin Exp Neuropsychol 2012;34:11–34. Full Text

141. Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(Suppl 3):S80–5. Full Text

142. McGuire LC, Ford ES, Ajani UA. Cognitive functioning as a predictor of functional disability in later life. Am J Geriatr Psychiatry 2006;14:36–42. Full Text

143. Fields JA, Machulda M, Aakre J, et al. Utility of the DRS for predicting problems in day-to-day functioning. Clin Neuropsychol 2010;24:1167–80. Full Text

144. Berlau DJ, Corrada MM, Kawas C. The prevalence of disability in the oldest-old is high and continues to increase with age: findings from The 90+ Study. Int J Geriatr Psychiatry 2009;24:1217–25. Full Text

145. Gill TM, Guo Z, Allore HG. The epidemiology of bathing disability in older persons. J Am Geriatr Soc 2006;54:1524–30. Full Text

146. Gill TM, Allore HG, Han L. Bathing disability and the risk of long-term admission to a nursing home. J Gerontol A Biol Sci Med Sci 2006;61:821–5. Full Text

147. Kingston A, Collerton J, Davies K, Bond J, Robinson L, Jagger C. Losing the ability in activities of daily living in the oldest old: a hierarchic disability scale from the Newcastle 85+ study. PLoS One 2012;7:e31665. Full Text

148. Ranganathan VK, Siemionow V, Sahgal V, Yue GH. Effects of aging on hand function. J Am Geriatr Soc 2001;49:1478–84. Full Text

149. Scherder E, Dekker W, Eggermont L. Higher-level hand motor function in aging and (preclinical) dementia: its relationship with (instrumental) activities of daily life—a mini-review. Gerontology 2008;54:333–41. Full Text

150. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med 1998;338:1035–41. Full Text

151. Evert J, Lawler E, Bogan H, Perls T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci 2003;58:232–7. Full Text

152. Cutler RG. Evolution of human longevity and the genetic complexity governing aging rate. Proc Natl Acad Sci U S A 1975;72:4664–8. Full Text

153. Schachter F. Causes, effects, and constraints in the genetics of human longevity. Am J Hum Genet 1998;62:1008–14. Full Text

154. Perls T. Dementia-free centenarians. Exp Gerontol 2004;39:1587–93. Full Text

155. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994;51:1198–204. Full Text